When injected before ischemic stroke [25] or during reperfusion [33], effectiveness of EPO reveals a larger therapeutic time-window when compared to rtPA, thus suggesting that rhEPO administration should be an effective treatment with a large time window following ischemic stroke, at least in young patients. This evidence concerns the gene EPO and ischemic stroke.